{
    "clinical_study": {
        "@rank": "55173", 
        "arm_group": {
            "arm_group_label": "Subjects with and without COPD", 
            "arm_group_type": "Experimental", 
            "description": "All subjecs will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function."
        }, 
        "brief_summary": {
            "textblock": "The overall objectives of our study are to determine the capabilities of hyperpolarized\n      129Xe MRI to measure lung function and its potential to sensitively detect pulmonary disease\n      and its progression in COPD. We hypothesize that measurement of alveolar surface area,\n      septal thickness, and capillary transit time measured with hyperpolarized 129Xe will\n      correlate better with quality of life measures in COPD subjects than traditional diagnostic\n      measures such as spirometry and Computed Tomography."
        }, 
        "brief_title": "Functional Applications of Hyperpolarized 129Xe MRI", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-80\n\n        For Healthy nonsmoker subjects:\n\n          -  No current physician diagnosed medical disease requiring active medication\n\n          -  No smoking history, defined as less than 100 cigarettes smoked in a lifetime\n\n          -  Normal spirometry: FEV1/FVC \u2265 0.70, FEV1 \u2265 80% predicted\n\n        For Subjects who have participated in the COPDGene Study\n\n          -  Post-bronchodilator spirometry: FEV1 > 40% predicted\n\n        Exclusion Criteria:\n\n          -  MR contraindications: e.g., electrical implants such as cardiac pacemakers,\n             ferromagnetic implants such as prostheses, claustrophobia\n\n          -  Pregnancy or suspected pregnancy\n\n          -  Use of continuous oxygen\n\n          -  Use of antibiotics and/or systemic corticosteroids (new prescription or increased\n             dose) for an exacerbation of lung disease or any lung infection in the past four\n             weeks\n\n          -  Uncontrolled cancer, as defined as ongoing radiation therapy, ongoing chemotherapy\n\n          -  A heart attack in the past three months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697332", 
            "org_study_id": "Hyperpolarized xenon", 
            "secondary_id": "5R01HL096471-03"
        }, 
        "intervention": {
            "arm_group_label": "Subjects with and without COPD", 
            "description": "800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.", 
            "intervention_name": "Hyperpolarized 129Xe gas", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "COPD", 
        "lastchanged_date": "October 1, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Brigham & Women's Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Samuel Patz, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Iga Muradyan, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "George Washko, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "James P Butler, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ritu Gill, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Functional Applications of Hyperpolarized 129Xe MRI", 
        "overall_contact": {
            "email": "muradian@bwh.harvard.edu", 
            "last_name": "Iga Muradyan, PhD", 
            "phone": "617-278-0501"
        }, 
        "overall_contact_backup": {
            "email": "patz@bwh.harvard.edu", 
            "last_name": "Samuel Patz, PhD", 
            "phone": "617-278-0616"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "Samuel Patz, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Hyperpolarized 129Xe MRI scans will be performed on healthy subjects and the uptake of 129Xe in the pulmonary septal tissue will be measured as a function of time. From this data, the mean and distribution of three pulmonary functional parameters will be determined. The three measures are alveolar surface area per unit volume, septal thickness and capillary transit time through the gas exchange region.", 
                "measure": "Baseline Statistics of Healthy Subjects", 
                "safety_issue": "No", 
                "time_frame": "At the end of a 4 year study."
            }, 
            {
                "description": "Hyperpolarized 129Xe MRI measures of disease severity in GOLD Stage 1-3 subjects are more highly correlated with physical disabilities associated with their pulmonary disease than traditional tests of pulmonary function.", 
                "measure": "Differences between healthy and diseased COPD subjects.", 
                "safety_issue": "No", 
                "time_frame": "At the end of a 4 year study."
            }, 
            {
                "description": "Determine the degree to which the spatial heterogeneity of regional 129Xe measurements of pulmonary function in a single individual correlates with physical manifestations of disease severity. We hypothesize that measures of spatial heterogeneity will correlate highly with physical disability.", 
                "measure": "Spatial Heterogeneity", 
                "safety_issue": "No", 
                "time_frame": "At the end of a 4 year study."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697332"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Samuel Patz", 
            "investigator_title": "Scientific Director, Center for Pulmonary Functional Imaging", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}